Copy
 
 
alt text
 
 

COMBACTE-NET Midterm Project Review Meeting

 

On Wednesday, January 25th all COMBACTE-NET Workpackage Leaders gathered at the Innovative Medicines Initiatives (IMI) Head Office in Brussels for the Midterm Project Review meeting. COMBACTE-NET started on January 1st 2013 and is scheduled to finish – after an extension for the newly incorporated clinical studies in the workpackages 6E, 7 and 8 - on 28th of February 2021.

 
Read full article
 
 
 
 
 
 
 

Dr. Biljana Carevic’s Success Story in the ASPIRE-ICU Study

 

COMBACTE-NET's ASPIRE-ICU Study Team spoke with Dr. Biljana Carevic, Principle Investigator and National Coordinator at the Clinical Center of Serbia located in Belgrade. Dr. Carevic is currently one of the top enrollers in the ASPIRE-ICU study.

 
Read full article
 
 
 
 
 
 
 

REJUVENATE Study Update

 

Owing to the continuous commitment of COMBACTE-CARE's REJUVENATE study sites, 7 new patients in France and Spain could be recruited within only 8 days. At the moment, 20 study patients have been or are being treated with ATM/AVI.

 
Read full article
 
 
 
 
 
 
 

EURECA Study Reaches 406 Patients

 

The number of enrollments in COMBACTE-CARE's EURECA study is steadily growing, reaching a number of 406 enrolled patients this month! There have been 31 sites initiated in 9 different countries: 1 from Albania, 1 from Croatia, 1 from Kosovo, 1 from Montenegro, 3 from Greece, 5 from Turkey, 5 from Serbia, 7 from Romania and 7 from Spain.

 
Read full article
 
 
 
 
 
 
 

Fighting the Enemy Within

 

Together with colleagues, COMBACTE-MAGNET's Evelina Tacconelli, Work Package Lead for EPI-Net, recently published an article on microbiome and R&D for new drugs effective against antibiotic-resistant bacteria. The article was published on February 17th in the Science journal.

 
Read full article
 
 
 
 
 
 
 

ASPIRE-ICU Study Reaches Targeted 30 Sites

 

With selecting the 4th site in Bulgaria this month, the ASPIRE-ICU study has now selected the targeted 30 sites for participation in the study.To ensure the pan-European continent is represented in this study, sites across the four sub-regions of Europe (as described by the United Nations) have been selected.

 
Read full article
 
 
 
 
 
 
 

ANTICIPATE Study Metrics

 

COMBACTE-NET's ANTICIPATE study has been initiated in 20 out of 30 sites, of which 6 sites are actively recruiting patients. The final Site Initiation Visits are being planned for February 2017. All sites are expected to recruit patients by the end of February.

 
Read full article
 
 
 
 
 
 
 

Want to read more?

 
 
 
Check out the newsroom
 
 
 
 
 

Upcoming events

 
 
 
 
 

Face to Face GCP Training Bulgaria

 
09/03/2017
1 day
Sofia, Bulgaria
 
 
 
 
 
 
 

COMBACTE Country Visit Croatia

 
11/04/2017
2 days
Zagreb, Croatia
 
 
 
 
 
 
 

COMBACTE at ECCMID 2017 Austria

 
22/04/2017
3 days
Vienna, Austria
 
 
 
 
 
 
Got great ideas for the newsletter?
 
 
Contact the PMO
 
 
 
 
 
 
 

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.